Abstract
Background Patients with repaired tetralogy of Fallot (rTOF) remain at risk of sustained monomorphic ventricular tachycardia (SMVT) related to slow-conducting anatomical isthmuses (SCAI). Invasive electroanatomical mapping (EAM) is the only available method to identify SCAI (SCAIEAM). We aimed to determine rTOF-specific high signal intensity threshold values (HSIt) to identify abnormal myocardium by 3D late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) and assess the performance of LGE-CMR to non-invasively identify SCAIEAM.
Methods Consecutive rTOF patients who underwent right ventricular EAM (RV-EAM) and 3D LGE-CMR were included (2012-2021). A SCAIEAM was defined as an anatomical isthmus (AI) with conduction velocity (CV) <0.5 m/s. LGE-CMR-derived 3D RV reconstructions were merged with 3D RV-EAM data. The HSIt was determined based on the comparison of local bipolar voltages (BV) and the corresponding local SI using ROC analysis. An abnormal AI on LGE-CMR (Abnormal AICMR) was defined as AI showing continuous high SI (>HSIt) between anatomical boundaries.
Results Forty-eight rTOF patients (34±16 years, 58% male) were included. Of 107 AIs on EAM (AI1 and 3 in all, AI2 in 11), 78 were normal-conducting AIEAM (NCAIEAM), 22 were SCAIEAM (SCAIEAM2 in 2 and SCAIEAM3 in 20), and 7 were blocked AIEAM3. All 14 induced SMVTs were related to SCAIEAM3. A total of 9240 EAM points were analyzed. HSIt was 42% of the maximal SI (AUC 0.80; sensitivity, 74%; specificity, 78%). On 3D-CMR RV construction, all 29 SCAIEAM or Blocked AIEAM were identified as abnormal AICMR. Among the 78 NCAIEAM, 70 were normal AICMR and 8 were abnormal AICMR. The sensitivity and specificity of 3D LGE-CMR for identifying SCAIEAM or blocked AIEAM were 100% and 90% (29/29 and 70/78), respectively. Among patients with NCAIEAM3 (n=28), those with abnormal AICMR3 (n=6) had significantly lower BV and slower CV compared with those with normal AICMR3 (n=22) (BV, 1.91 [1.62-2.60] vs. 3.45 mV [2.22-5.67]; CV, 0.69 [0.62-0.81] vs, 0.95 m/s [0.82-1.09]; both P<0.01).
Conclusion 3D LGE-CMR can identify SCAI with excellent sensitivity and specificity and may identify diseased AI3 even before critical conduction delay occurs, which may enable non-invasive risk stratification of VT and may refine patient selection for invasive EAM.
What is new?
rTOF-specific high signal intensity threshold (HSIt) value on 3D LGE-CMR to identify abnormal myocardium was determined by direct comparison between 9240 superimposed 3D EAM points and corresponding local signal intensity on the 3D CMR-derived reconstruction.
The newly proposed method of CMR image analysis using the obtained HSIt showed an excellent interobserver agreement and could identify SCAI or blocked AI with 100% sensitivity and 90% specificity.
Compared to patients with NCAIEAM and normal AICMR (true negative CMR), those with NCAIEAM but abnormal AICMR (false positive CMR) had already significantly lower BV and CV on EAM.
What are the clinical implications?
The newly proposed technique of 3D LGE-CMR image analysis may allow for non-invasive and serial risk stratification of VT in patients with rTOF and can refine patient selection for invasive EAM and concomitant ablation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge the support from the Netherlands Cardiovascular Research lnitiative: An initiative with support of the Dutch Heart Foundation and Hartekind, CVON2019-002 OUTREACH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
internal review board of the Leiden University Medical Center gave ethical approval for this work. The medisch-ethische toetsingscommissie (METC Leiden Den Haag Delft) waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
To maintain patient confidentiality, data and study materials will not be made available to other researchers for purposes of replicating the results.
